

REVIEW ARTICLE

Covid-19 and the digestive system

Sunny H Wong,^{*,†} Rashid NS Lui^{*,†} and Joseph JY Sung^{*,†}^{*}Institute of Digestive Disease, and [†]Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong**Key words**

coronavirus, Covid-19, diarrhea, gastrointestinal infection, pneumonia.

Accepted for publication 24 March 2020.

CorrespondenceProfessor Joseph JY Sung, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9/F Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong.
Email: jjysung@cuhk.edu.hk**Declaration of conflict of interest:** The authors declare no conflict of interest.**Abstract**

The novel coronavirus disease is currently causing a major pandemic. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the *Betacoronavirus* genus that also includes the SARS-CoV and Middle East respiratory syndrome coronavirus. While patients typically present with fever and a respiratory illness, some patients also report gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain. Studies have identified the SARS-CoV-2 RNA in stool specimens of infected patients, and its viral receptor angiotensin converting enzyme 2 was found to be highly expressed in gastrointestinal epithelial cells. These suggest that SARS-CoV-2 can actively infect and replicate in the gastrointestinal tract. This has important implications to the disease management, transmission, and infection control. In this article, we review the important gastrointestinal aspects of the disease.

Introduction

The novel coronavirus disease (Covid-19) is causing a major pandemic. As of 23 March 2020, it has infected over 340,000 people worldwide and caused over 14,000 deaths. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-sense single-stranded RNA virus and is taxonomically a member of the *Betacoronavirus* genus. Patients typically present with fever and respiratory symptoms, nevertheless, some patients also have gastrointestinal manifestations with diarrhea, vomiting, and abdominal pain.¹ Studies have identified the SARS-CoV-2 RNA in anal/rectal swabs^{2,3} and stool specimens^{4–6} of Covid-19 patients, even after the clearance of the virus in the upper respiratory tract.^{2,3} Furthermore, the viral receptor angiotensin converting enzyme 2 (ACE2) was found to be expressed in gastrointestinal epithelial cells.^{7,8} Together these suggest that SARS-CoV-2 can actively infect and replicate in the gastrointestinal tract. This has important implications to the disease management, transmission, and infection control. In this article, we review the important gastrointestinal aspects of the disease.

Gastrointestinal symptoms of Covid-19 patients

While Covid-19 patients typically present with a respiratory illness, some patients reported gastrointestinal symptoms including diarrhea, vomiting, and abdominal pain during course of the disease. In the first case of Covid-19 in a 35-year-old man in the United States,⁴ the patient presented with a 2-day history of nausea and vomiting upon hospital admission, followed by diarrhea and abdominal discomfort on the second day of hospitalization. The SARS-CoV-2 RNA was detected in stool of the patient by reverse

transcriptase polymerase chain reaction on illness day 7.⁴ Similarly, in the familial cluster of Covid-19 cases during the early epidemic,⁹ diarrhea was described in two young adults (aged 36 and 37 years) out of the six patients, with reported bowel openings of up to eight times a day.

Subsequent cohorts have consistently reported gastrointestinal symptoms among Covid-19 patients. In a large study that collected data from 1,099 patients from 552 hospitals in China, it reported nausea or vomiting in 55 (5.0%) and diarrhea in 42 (3.8%) patients.¹⁰ Several other cohorts have reported frequencies of diarrhea ranging 2.0–10.1% and nausea and/or vomiting ranging 1.0–10.1% (Table 1).^{11–18,20} In the cohort of 140 Covid-19 patients in Wuhan, gastrointestinal symptoms were described in up to 39.6% of the patients,¹⁹ including nausea in 24 (17.3%), diarrhea in 18 (12.9%), and vomiting in 7 (5.0%) patients. Similarly, the rate of diarrhea was up to 35.6% in a cohort of 73 patients.⁷ These rates were higher than some other cohorts and highlighted the variability of clinical presentations. On the other hand, abdominal pain or discomfort was sparingly described⁴ and was reported in 2.2–5.8% in patient cohorts^{16,19}(Table 1).

Similar to adults, gastrointestinal symptoms were observed in a cohort of 171 pediatric patients with Covid-19.¹⁴ Diarrheal and vomiting were observed in 15 (8.8%) and 11 (6.4%) of these children, respectively. In another study that investigated viral shedding in pediatric Covid-19 patients, diarrhea was observed in 3 out of the 10 infected children.³ Although different clinical features, such as a milder disease course¹⁴ and less respiratory symptoms³ have been proposed in Covid-19 children, the gastrointestinal symptoms appear to be similar, although more clinical data are needed to arrive at such a conclusion.

It is evident that patients can present with gastrointestinal symptoms early in the disease course. For example, the first Covid-19 patient in the USA had nausea and vomiting 2 days before going

Table 1 Presentation of gastrointestinal symptoms in coronavirus infection: a comparison of Covid-19, SARS, and MERS in major clinical cohorts

	Subject	Diarrhea	Nausea	Vomiting	Abdominal pain
Covid-19					
Chen N <i>et al</i> ¹¹	99	2 (2.0%)	1 (1%)	1 (1%)	NA
Guan W <i>et al</i> ¹⁰	1099	42 (3.8%)	55 (5.0%)	55 (5.0%)	NA
Huang C <i>et al</i> ¹²	38	1 (2.6%)	NA	NA	NA
Liu K <i>et al</i> ¹³	137	11 (8%)	NA	NA	NA
Lu X <i>et al</i> ¹⁴	171	15 (8.8%)	NA	11 (6.4%)	NA
Shi H <i>et al</i> ¹⁵	81	3 (3.7%)	NA	4 (4.9%)	NA
Wang D <i>et al</i> ¹⁶	138	14 (10.1%)	14 (10.1%)	5 (3.6%)	3 (2.2%)
Xiao F <i>et al</i> ⁷	73	26 (35.6%)	NA	NA	NA
Xu XW <i>et al</i> ¹⁷	62	3 (4.8%)	NA	NA	NA
Yang X <i>et al</i> ¹⁸	52	NA	NA	2 (3.8%)	NA
Zhang JJ <i>et al</i> ¹⁹	139	18 (12.9%)	24 (17.3%)	7 (5.0%)	8 (5.8%)
Zhou F <i>et al</i> ²⁰	141	9 (4.7%)	7 (3.7%)	7 (3.7%)	NA
SARS					
Booth CM <i>et al</i> ²¹	144	34 (23.6%)	28 (19.4)	28 (19.4)	5 (5.0%)
Cheng VC <i>et al</i> ²²	142	69 (48.6%)	NA	NA	NA
Choi KW <i>et al</i> ²³	267	41 (15.4%)	NA	19 (7.1%)	NA
Jang TN <i>et al</i> ²⁴	29	4 (13.8%)	5 (17.2%)	5 (17.2%)	NA
Kwan AC <i>et al</i> ²⁵	240	49 (20.4%)	NA	NA	NA
Lee N <i>et al</i> ²⁶	138	27 (19.6%)	27 (19.6%)	27 (19.6%)	NA
Leung CW <i>et al</i> ²⁷	44	9 (20.5%)	13 (29.5%)	13 (29.5%)	4 (9.1%)
Leung WK <i>et al</i> ²⁸	138	53 (38.4%)	NA	NA	NA
Liu CL <i>et al</i> ²⁹	53	35 (66.0%)	6 (11.3%)	5 (9.4%)	5 (9.4%)
Peiris JS <i>et al</i> ³⁰	75	55 (73.3%)	NA	NA	NA
MERS					
Al Ghamdi M <i>et al</i> ³¹	51	13 (25.5%)	NA	12 (23.5%)	NA
Almekhlafi GA <i>et al</i> ³²	31	6 (19.4%)	NA	4 (12.9%)	9 (29.0%)
Arabi YM <i>et al</i> ³³	330	38 (11.5%)	58 (17.6%)	58 (17.6%)	47 (14.2%)
Assiri A <i>et al</i> ³⁴	47	12 (25.5%)	10 (21.2%)	10 (21.2%)	8 (17.0%)
Assiri A <i>et al</i> ³⁵	23	5 (21.7%)	NA	4 (17.4%)	NA
Choi WS <i>et al</i> ³⁶	186	36 (19.4%)	26 (14.0%)	26 (14.0%)	15 (8.1%)
Kim KM <i>et al</i> ³⁷	36	7 (19.4%)	5 (13.9%)	5 (13.9%)	NA
Nam HS <i>et al</i> ³⁸	25	8 (32.0%)	8 (32.0%)	8 (32.0%)	8 (32.0%)
Saad M <i>et al</i> ³⁹	70	21 (30%)	NA	21 (30%)	17 (24.3%)
Sherbini N <i>et al</i> ⁴⁰	29	8 (27.6%)	8 (27.6%)	8 (27.6%)	NA

Case reports, series, or cohorts with less than 20 subjects are not included.

Covid-19, novel coronavirus disease; MERS, Middle East Respiratory Syndrome Coronavirus; SARS, severe acute respiratory syndrome coronavirus.

to hospital, and developed diarrhea on the second day of admission,⁴ whereas the two young adults in the early familial Covid-19 cluster had diarrhea upon presentation to the hospital.⁹ Diarrhea can be one initial symptom and may even occur earlier than pyrexia or respiratory symptoms in some cases.^{13,16}

Diarrhea was a common symptom of SARS during its outbreak back in 2003. Among the SARS patients in Hong Kong, approximately 20% had with diarrhea on disease presentation.^{26,28} The mean duration of diarrhea was 3.7 days, and most was self-limiting.²⁸ There were higher rates of diarrhea during the course of illness,^{22,28,29} up to 73% of SARS patients in one study³⁰ (Table 1). Gastrointestinal symptoms were also frequent in Middle East respiratory syndrome coronavirus (MERS),⁴¹ with cohorts reporting diarrhea, nausea, vomiting, and abdominal pain in 11.5–32% of the patients (Table 1). Comparing with these figures, the gastrointestinal symptoms in Covid-19 appeared to be less common (Table 1). This may signify the differences in viral tropism as compared with SARS-CoV and MERS-CoV.

Liver injury in Covid-19 patients

Apart from gastrointestinal symptoms, patients with Covid-19 can have liver injury with raised enzymes found in blood tests. Current data indicated that 14.8–53.1% of Covid-19 patients had abnormal levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the course of disease, with mostly mild elevation in serum bilirubin.^{10–12,15–18,42} In a commentary that described a cohort of 56 Covid-19 patients, gamma-glutamyl transferase (GGT) was elevated in 54% of the patients.⁴³ Most of the liver injuries are mild and transient, although severe liver damage can occur. The proportion of liver injury was also higher in patients with severe Covid-19 disease.^{10,12} In the cohort that described 99 patients in Wuhan, 43 patients had raised ALT or AST; one patient with critical Covid-19 had severe hepatitis with serum ALT increased up to 7590 U/L.¹¹

While the mechanism of liver injury is not fully understood, the injury can be because of direct viral infection of hepatocytes,

immune-related injury, or drug hepatotoxicity.⁴⁴ There is also suggestion that the virus may bind to cholangiocytes through the ACE2 receptor to dysregulate the liver function.⁴³ Notably, histological examination of the liver biopsy from a deceased Covid-19 patient showed microvesicular steatosis and mild lobular activity.⁴⁵ These histological changes could be caused by SARS-CoV-2 infection or drug-induced liver injury. Nevertheless, no viral inclusion was observed in the liver. It remains to be studied whether SARS-CoV-2 may target the liver in a similar manner to SARS-CoV,^{46–48} and whether other mechanisms play an important role in the liver injury.

Mechanisms of gastrointestinal tract involvement

Evidence from previous SARS studies indicated that coronavirus has a tropism to the gastrointestinal tract. The SARS-CoV RNA could be readily detected in stool specimens of SARS patients,⁴⁹ and electron microscopy on biopsy and autopsy specimens showed active viral replications in both small and large intestines.²⁸ Similarly, enteric infection could occur with MERS-CoV, as human intestinal epithelial cells were highly susceptible to the virus and could sustain robust viral replication.⁵⁰ This gastrointestinal tropism may explain the frequent occurrence of diarrhea in coronavirus infection. This fecal source can lead to fomite transmission, especially when infective aerosols are generated from the toilet plume.⁵¹

Although at a lower frequency compared with SARS, some Covid-19 patients do develop diarrhea during their disease course. This suggests the possible tropism of SARS-CoV-2 to the gastrointestinal tract. Genome sequences showed that SARS-CoV-2 shared 79.6% sequence identity to SARS-CoV, both encoding and expressing the spike (S) glycoproteins that could bind to the entry receptor ACE2 to enter human cells.^{52–54} The receptor binding domain on SARS-CoV-2 could bind to human ACE2 with high affinity, correlating with the efficient spread of the virus among humans.^{55,56} While ACE2 is highly expressed in type II alveolar cells (AT2) in the lungs, the receptor is also abundantly expressed in the gastrointestinal tract, especially in the small and large intestines.^{7,8} Staining of viral nucleocapsid protein was visualized in cytoplasm of gastric, duodenal, and rectal epithelium.⁴² These data have provided valuable insights into the receptor-mediated entry into the host cells and provided basis for its possible transmission route through the fecal contents.

Implications to patient care and infection control

The tropism of SARS-CoV-2 to the gastrointestinal tract, its positive detection in stool, and its associated gastrointestinal symptoms, have important implications to both patient care and infection control. Clinicians should be alert of the gastrointestinal symptomatology of Covid-19, especially as they may occur before the onset of pyrexia and respiratory symptoms.

More importantly, several studies have demonstrated the presence of viral RNA in stool or anal/rectal swabs of Covid-19 patients.^{2–6} In a study that evaluated 73 Covid-19 patients, 39 (53.4%) were tested positive for SARS-CoV-2 RNA in stool, with a duration of positive stool ranging from 1 to 12 days. Rather of

concern, 17 (23.3%) patients remained positive with stool viral RNA after showing negative in their respiratory samples.⁷ In another study that followed 10 pediatric patients and evaluated their nasopharyngeal and rectal swabs, eight children were persistently tested positive on rectal swabs even after nasopharyngeal clearance of the virus.³ Moreover, two children had positive rectal swabs, despite after clearance with two consecutive negative rectal swabs separated by at least 24 h apart.⁴⁶ In contrast to the cycle threshold (Ct) value of 36–38 on illness Day 7 stool sample from the first US case,⁴ the longitudinal Ct values in the pediatric patients were mostly below 35.³ This suggested that viral shedding from the gastrointestinal tract may be abundant and may last long after resolution of clinical symptoms. Indeed, a previous study of SARS-CoV indicated that viral RNA could still be detected after 30 days in stool of SARS patients.⁵⁷ Nevertheless, the viral dynamic of SARS-CoV-2 in the gastrointestinal tract is not known and may not follow that of SARS-CoV as observed in the respiratory tract.^{30,58}

The immediate implication of these data is certainly on the disease infectivity. A recent environmental study suggested that SARS-CoV-2 could remain viable in aerosols for hours and could stay stably on plastic and stainless steel for at least 72 h.⁵⁹ While more studies are needed to demonstrate its replication competence, its abundance in stool and stability in environment would pose SARS-CoV-2 favorably to spread among human hosts. This fecal source can lead to viral transmission especially when aerosols are generated, as with the major outbreak caused by toilet fume in Amoy Garden during the SARS epidemics in Hong Kong.⁵¹ The gastrointestinal involvement of Covid-19 would necessitate a need to consider several clinical policies, such as incorporation of rectal swab testing before discharging patients,⁶⁰ as well as our preparedness for personal protective equipment in the endoscopy setting.⁶¹ These considerations will be important in our battle against Covid-19.

References

- Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. *Gastroenterology* 2020.
- Zhang W, Du RH, Li B *et al.* Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg. Microbes. Infect.* 2020; **9**: 386–9.
- Xu Y, Li X, Zhu B *et al.* Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat. Med.* 2020.
- Holshue ML, DeBolt C, Lindquist S *et al.* First case of 2019 novel coronavirus in the United States. *N. Engl. J. Med.* 2020; **382**: 929–36.
- Tang A, Tong ZD, Wang HL *et al.* Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. *Emerg. Infect. Dis.* 2020; **26**.
- Young BE, Ong SWX, Kalimuddin S *et al.* Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA* 2020.
- Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology* 2020.
- Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett.* 2002; **532**: 107–10.
- Chan JF, Yuan S, Kok KH *et al.* A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; **395**: 514–23.

- 10 Guan WJ, Ni ZY, Hu Y *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 2020.
- 11 Chen N, Zhou M, Dong X *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507–13.
- 12 Huang C, Wang Y, Li X *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 13 Liu K, Fang YY, Deng Y *et al.* Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020.
- 14 Lu X, Zhang L, Du H *et al.* SARS-CoV-2 infection in children. *N. Engl. J. Med.* 2020.
- 15 Shi H, Han X, Jiang N *et al.* Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect. Dis.* 2020.
- 16 Wang D, Hu B, Hu C *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020.
- 17 Xu XW, Wu XX, Jiang XG *et al.* Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020; **368**: m606.
- 18 Yang X, Yu Y, Xu J *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir. Med.* 2020.
- 19 Zhang JJ, Dong X, Cao YY *et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020.
- 20 Zhou F, Yu T, Du R *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020.
- 21 Booth CM, Matukas LM, Tomlinson GA *et al.* Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA* 2003; **289**: 2801–9.
- 22 Cheng VC, Hung IF, Tang BS *et al.* Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. *Clin. Infect. Dis.* 2004; **38**: 467–75.
- 23 Choi KW, Chau TN, Tsang O *et al.* Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. *Ann. Intern. Med.* 2003; **139**: 715–23.
- 24 Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. *J. Infect.* 2004; **48**: 23–31.
- 25 Kwan AC, Chau TN, Tong WL *et al.* Severe acute respiratory syndrome-related diarrhea. *J. Gastroenterol. Hepatol.* 2005; **20**: 606–10.
- 26 Lee N, Hui D, Wu A *et al.* A major outbreak of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.* 2003; **348**: 1986–94.
- 27 Leung CW, Kwan YW, Ko PW *et al.* Severe acute respiratory syndrome among children. *Pediatrics* 2004; **113**: e535–43.
- 28 Leung WK, To KF, Chan PK *et al.* Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. *Gastroenterology* 2003; **125**: 1011–7.
- 29 Liu CL, Lu YT, Peng MJ *et al.* Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever. *Chest* 2004; **126**: 509–17.
- 30 Peiris JS, Chu CM, Cheng VC *et al.* Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* 2003; **361**: 1767–72.
- 31 Al Ghamdi M, Alghamdi KM, Ghandoor Y *et al.* Treatment outcomes for patients with Middle Eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. *BMC Infect. Dis.* 2016; **16**: 174.
- 32 Almekhlafi GA, Albarrak MM, Mandourah Y *et al.* Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. *Crit. Care* 2016; **20**: 123.
- 33 Arabi YM, Al-Omari A, Mandourah Y *et al.* Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. *Crit. Care Med.* 2017; **45**: 1683–95.
- 34 Assiri A, Al-Tawfiq JA, Al-Rabeeh AA *et al.* Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect. Dis.* 2013; **13**: 752–61.
- 35 Assiri A, McGeer A, Perl TM *et al.* Hospital outbreak of Middle East respiratory syndrome coronavirus. *N. Engl. J. Med.* 2013; **369**: 407–16.
- 36 Choi WS, Kang CI, Kim Y *et al.* Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea. *Infect. Chemother.* 2016; **48**: 118–26.
- 37 Kim KM, Ki M, Cho SI *et al.* Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary's Hospital. *Epidemiol. Health* 2015; **37**: e2015041.
- 38 Nam HS, Park JW, Ki M, Yeon MY, Kim J, Kim SW. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. *Int. J. Infect. Dis.* 2017; **58**: 37–42.
- 39 Saad M, Omrani AS, Baig K *et al.* Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. *Int. J. Infect. Dis.* 2014; **29**: 301–6.
- 40 Sherbini N, Iskandrani A, Kharaba A, Khalid G, Abduljawad M, Al-Jahdali H. Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: demographic, clinical and survival data. *J. Epidemiol. Glob. Health.* 2017; **7**: 29–36.
- 41 Chan JF, Lau SK, Tos K, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. *Clin. Microbiol. Rev.* 2015; **28**: 465–522.
- 42 Zhao D, Yao F, Wang L *et al.* A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. *Clin. Infect. Dis.* 2020.
- 43 Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol. Hepatol.* 2020.
- 44 Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int.* 2020.
- 45 Xu Z, Shi L, Wang Y *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 2020.
- 46 Ding Y, He L, Zhang Q *et al.* Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *J. Pathol.* 2004; **203**: 622–30.
- 47 Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* 2004; **203**: 631–7.
- 48 Tan YJ, Fielding BC, Goh PY *et al.* Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. *J. Virol.* 2004; **78**: 14043–7.
- 49 Hung IF, Cheng VC, Wu AK *et al.* Viral loads in clinical specimens and SARS manifestations. *Emerg. Infect. Dis.* 2004; **10**: 1550–7.
- 50 Zhou J, Li C, Zhao G *et al.* Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Sci. Adv.* 2017; **3**: eaao4966.
- 51 Yu IT, Li Y, Wong TW *et al.* Evidence of airborne transmission of the severe acute respiratory syndrome virus. *N. Engl. J. Med.* 2004; **350**: 1731–9.

- 52 Zhou P, Yang XL, Wang XG *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270–3.
- 53 Hoffmann M, Kleine-Weber H, Schroeder S *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020.
- 54 Lu R, Zhao X, Li J *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; **395**: 565–74.
- 55 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 2020.
- 56 Wrapp D, Wang N, Corbett KS *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020; **367**: 1260–3.
- 57 Chan KH, Poon LL, Cheng VC *et al.* Detection of SARS coronavirus in patients with suspected SARS. *Emerg. Infect. Dis.* 2004; **10**: 294–9.
- 58 Zou L, Ruan F, Huang M *et al.* SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N. Engl. J. Med.* 2020; **382**: 1177–9.
- 59 van Doremalen N, Bushmaker T, Morris DH *et al.* Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N. Engl. J. Med.* 2020.
- 60 Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? *Lancet Gastroenterol. Hepatol.* 2020; **5**: 335–7.
- 61 Repici A, Maselli R, Colombo M *et al.* Coronavirus (COVID-19) outbreak: what the department of endoscopy should know. *Gastrointest. Endosc.* 2020.